INITIAL GOALS

Operationalize GBM AGILE into a self-sustaining
engine of therapeutic and biomarker development
for patients with GBM.
Finance the launch and ongoing activity of new
GBM-focused therapies developed through
GBM AGILE.
Use GBM AGILE as a model for developing an efficient
framework for the discovery and development of
therapies and biomarkers for other rare and deadly diseases.
Randall Garnick Photography, National Brain Tumor Society

LEADERSHIP

The Global Coalition for Adaptive Research (GCAR) is an international partnership

The Global Coalition for Adaptive Research (GCAR) is an international partnership comprised of some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary—the patient—is supported in the fight against rare and deadly diseases.

READ MORE

GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma.

GBM AGILE is changing the IDEA of clinical trials

Innovative – Next-generation trial that will lower cost of development and speed progress.

Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.

Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug's effectiveness.

Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
LEARN MORE

NEWS

Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma
SEPTEMBER 21, 2022  |  BUSINESSWIRE
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM AGILE Trial
JULY 6, 2022  |  BUSINESSWIRE
GBM AGILE Opens to Paxalisib in Europe
MAY 31, 2022  |  KAZIA THERAPEUTICS
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
MAY 27, 2022  |  PRNEWSWIRE
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID
MAY 19, 2022  |  BUSINESSWIRE
Cure Brain Cancer Foundation invests in GBM AGILE, connecting Australians to an innovative clinical trial program to treat glioblastoma
FEBRUARY 22, 2022  |  CURE BRAIN CANCER FOUNDATION
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
JANUARY 20, 2022  |  VIGEO THERAPEUTICS
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19
JANUARY 18, 2022  |  JAMA
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
JANUARY 18, 2022  |  BUSINESSWIRE
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma
NOVEMBER 30, 2021  |  PRNEWSWIRE
ALL NEWS

GET INVOLVED

CONTACT US

For additional information about GCAR and to learn how you can collaborate with us, please contact:
GENERAL INQUIRIES
MEDIA INQUIRIES